Search

Your search keyword '"Dirchwolf M"' showing total 72 results

Search Constraints

Start Over You searched for: Author "Dirchwolf M" Remove constraint Author: "Dirchwolf M"
72 results on '"Dirchwolf M"'

Search Results

1. Spontaneous bacterial peritonitis in patients with cirrhosis: incidence, outcomes, and treatment strategies

3. A global research priority agenda to advance public health responses to fatty liver disease

4. Access to direct-acting antivirals for the treatment of hepatitis C in a country with limited resources

5. Global multi-stakeholder endorsement of the MAFLD definition

6. A multi-society Delphi consensus statement on new fatty liver disease nomenclature

7. Evaluación de fibrosis en pacientes con enfermedad por hígado graso no alcohólico: adherencia a los algoritmos propuestos y barreras para cumplir con ellos

9. Evaluación del acceso a antivirales para el tratamiento de la hepatitis C en un país con recursos limitados

11. Evaluación de fibrosis en pacientes con enfermedad de hígado graso no alcohólico: adherencia a algoritmos propuestos y barreras para cumplir con ellos

12. Fibrosis assessment in patients with nonalcoholic fatty liver disease: Adherence to proposed algorithms and barriers to complying with them

13. A multi-society Delphi consensus statement on new fatty liver disease nomenclature

14. Global multi-stakeholder endorsement of the MAFLD definition

15. Towards evidence-based empiric antibiotic recommendations for spontaneous infections in patients with cirrhosis.

16. An artificial intelligence-generated model predicts 90-day survival in alcohol-associated hepatitis: A global cohort study.

17. Development and external validation of a model to predict multidrug-resistant bacterial infections in patients with cirrhosis.

19. Procedural-Related Bleeding in Hospitalized Patients With Liver Disease (PROC-BLeeD): An International, Prospective, Multicenter Observational Study.

20. Clinical and microbiological characteristics of bacterial infections in patients with cirrhosis. A prospective cohort study from Argentina and Uruguay.

21. Norfloxacin prophylaxis effect on multidrug resistance in patients with cirrhosis and bacterial infections.

22. The impact of perceived donor liver quality on post-transplant outcome.

23. Challenges and recommendations when selecting empirical antibiotics in patients with cirrhosis.

24. MELD 3.0 adequately predicts mortality and renal replacement therapy requirements in patients with alcohol-associated hepatitis.

27. Use of statins after liver transplantation is associated with improved survival: results of a nationwide study.

28. The MELD upgrade exception: a successful strategy to optimize access to liver transplantation for patients with high waiting list mortality.

29. The establishment of public health policies and the burden of non-alcoholic fatty liver disease in the Americas.

30. From Child-Pugh to MELD score and beyond: Taking a walk down memory lane.

31. Identification of optimal therapeutic window for steroid use in severe alcohol-associated hepatitis: A worldwide study.

32. Failure in all steps of hepatocellular carcinoma surveillance process is frequent in daily practice.

33. NAFLD: Challenges and opportunities to address the public health problem in Latin America.

34. The Latin American Association for the Study of the Liver (ALEH) position statement on the redefinition of fatty liver disease.

35. Outbreak of hepatitis A in a post-vaccination era: High rate of co-infection with sexually transmitted diseases.

36. Latin American Association for the study of the liver (ALEH) practice guidance for the diagnosis and treatment of non-alcoholic fatty liver disease.

38. Argentinian clinical practice guideline for surveillance, diagnosis, staging and treatment of hepatocellular carcinoma.

39. Biomarkers in Hepatocellular Carcinoma: Diagnosis, Prognosis and Treatment Response Assessment.

40. Medical management of metabolic and cardiovascular complications after liver transplantation.

41. [Diagnosis and treatment of non-alcoholic fatty liver disease. Argentine Association for the Study of Liver Diseases, year 2019].

42. Impact of acute-on-chronic liver failure on post-transplant survival and on kidney outcomes.

43. Spontaneous bacterial peritonitis recurrence in patients with cirrhosis receiving secondary prophylaxis with norfloxacin.

44. Unresolved issues in the prophylaxis of bacterial infections in patients with cirrhosis.

45. Review article: drug-induced liver injury in the context of nonalcoholic fatty liver disease - a physiopathological and clinical integrated view.

46. Trends in liver transplantation for hepatitis C in a country with reduced access to direct-acting antiviral agents.

47. Spontaneous bacteremia and spontaneous bacterial peritonitis share similar prognosis in patients with cirrhosis: a cohort study.

48. The Clinical Features of Patients with Chronic Hepatitis C Virus Infections Are Associated with Killer Cell Immunoglobulin-Like Receptor Genes and Their Expression on the Surface of Natural Killer Cells.

49. A Dynamic Definition of Acute Kidney Injury Does not Improve Prognosis Assessment in Acutely Decompensated Patients with Cirrhosis.

50. Clinical epidemiology of acute hepatitis C in South America.

Catalog

Books, media, physical & digital resources